COMPARE ANTIVIRAL EFFICACY OF ORALTDF & SUBCUTANEOUSTFV IN SIV-INFECTED MACAQUES

比较 ORALTDF 的抗病毒功效

• 批准号: 8357301
• 负责人: KOEN K VAN ROMPAY
• 金额: $ 19.14万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357301
• 关键词: Antiviral Agents; California; Drug Kinetics; Fumarates; Funding; Grant; Macaca; National Center for Research Resources; Primates; Principal Investigator; Prodrugs; Research; Research Infrastructure; Resources; SIV; Source; Tenofovir; United States National Institutes of Health; cost

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The study will compare the antiviral efficacy and pharmacokinetics of the parenteral compound tenofovir and its prodrug tenofovir disoproxyl fumarate in groups of SIV-infected macaques.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 该研究将比较肠胃外化合物替诺福韦的抗病毒功效和药代动力学及其在SIV感染的猕猴中的前药替代性替诺福韦毒氧基。